Introduction
Breast cancer is one of the most common causes of cancerrelated death in women over the world. Approximately 230,000 new cases of invasive breast cancer are expected to be diagnosed in the USA in 2012, and almost 40,000 women will die from this disease [1] . Although therapeutic approaches, such as surgery, chemotherapy, radiation, endocrine therapy, and targeted therapy, have reduced cancerspecific mortality, there still are many therapeutic failures which result in cancer recurrence, metastasis and death.
The "seed and soil" hypothesis postulates that an appropriate host microenvironment (the soil) is needed for the optimal growth of tumor cells (the seed) [2] . In the past four decades, many researchers have focused primarily on tumor cells. However, emerging evidence indicates that tumors are composed of tumor parenchyma and stroma, two discrete but interactive parts that cross-talk to promote tumor growth. Recently, many investigations support the notion that tumor stromal cells play important roles in tumor initiation, progression, and metastasis. Cancer-associated fibroblasts (CAFs) are the most frequent component of tumor stroma, especially in breast and pancreatic cancers [3, 4] . Increasing data indicate that the depletion of fibroblast activation protein (FAP)-expressing tumor stromal cells led to stunted tumor growth and improved response to tumor vaccination, providing evidence that the tumor microenvironment is a fertile ground for the development of novel therapies with the potential of augmenting existing treatment and prevention options [4, 5] . Actually, some new related therapeutic targets have been developed and are under preclinical evaluation and clinical trials, as shown in Table 1 . Herein, we review the current understandings of tumor stroma interacting with breast cancer cells, with special focus on CAFs. In addition, we also review new emerging fields in breast cancer therapy associated with other tumor stromal cells.
Cancer-associated fibroblasts

Origin and markers of CAFs
Fibroblasts are the most abundant cells in connective tissues and form a framework of tissues by secreting extracellular matrix (ECM) components [6] . In the past years, fibroblasts were found to be activated in wound healing and fibrosis with increasing expression of alpha smooth muscle actin (α-SMA) and the ED-A splice of fibronectin [6] . Currently, in agreement with the concept that tumors are similar to a chronic non-healing wound, fibroblasts have been found to be activated in cancer. These activated fibroblasts, termed cancer-associated fibroblasts [7] , share many similarities with activated fibroblasts found in wounds and inflammatory sites. Currently, there is no precise definition of CAFs because of the different cellular origins and expression markers. As shown in Fig. 1 , some evidence suggests that the origins of CAFs are (1) activated resident fibroblasts; (2) bone-marrowderived mesenchymal stem cells (MSCs); (3) cancer cells that undergo epithelial-mesenchymal transition (EMT); and (4) other mechanisms. For the first origin, there is evidence suggesting that the activation of resident fibroblasts is induced by many cancer-secreted factors, such as TGF-β and CXCL12/ SDF-1 [8] , or by losing suppressor genes, such as PTEN, CAV-1, p53, and p21 [9] [10] [11] [12] [13] [14] [15] . These hypotheses are also consistent with breast cancer xenograft models [8] . For the second source of CAFs, one study shows that in vivo, labeled MSCs have been found localized within tumor mass and differentiated into CAFs and pericytes with high expressions of α-SMA, FAP, tenascin-C, etc. [16] ; moreover, TGF-β1 from the conditioned medium of MCF7 and MDA-MB-231 promote the differentiation of human adipose tissue-derived stem cells into a CAF-like myofibroblastic phenotype (e.g., expression of α-SMA and tenascin-C) via Smad3 [17] , which suggests that CAFs also derive from other kinds of stem cells. The third source of CAFs is malignant tumor cells that undergo EMT changes [3, 16] . Malignant epithelial cancer cells can obtain high invasive and metastatic characteristics by exposure to many factors (i.e., PDGF, TGF-β, EGF, etc.). Moreover, CAFs may arise from endothelial cells by the endothelial-tomesenchymal transition with CD31 loss and higher expression of α-SMA and fibroblast-specific protein (FSP)-1 [18] . At present, no evidence suggests which origin of CAFs is dominant, and it is the same situation in the markers of CAFs. The acceptable markers of CAFs consist of high expressions of α-SMA, FSP-1, FAP, platelet-derived growth factor-α receptor (PDGFR-α), platelet-derived growth factor-β receptor (PDGFR-β), and vimentin or loss of CAV-1, PTEN, p21, or TP53 mutation [9] [10] [11] [12] [13] [14] [15] . Furthermore, CAFs of different tissue origins may express different markers. In breast cancer, some groups use FAP as an important marker [5, 19] , while other groups suggest that the combination of PDGFR-α and α-SMA is a distinguishing marker [20] . However, some findings confirm that the CAF marker is mainly dependent on the tissue origin [21] . Recently, one study used the 4T1 breast cancer model and Rip tag2 pancreatic cancer model to find whether these markers overlap in tumor stroma. The results indicated that α-SMA, PDGFR-β, and NG2 (chondroitin sulfate proteoglycan) significantly overlap each other in identifying a mixed population of fibroblasts (CAFs, myofibroblasts, pericytes, and vascular smooth muscle cells), while α-SMA or vimentin alone is not a suitable marker for CAFs, but FSP1 alone can identify a unique group of CAFs without other marker expressions [22] . The evidence above indicates that CAFs are also heterogeneous, like tumor cells, within the same type of cancer. Since breast cancer has been divided into [24, 25] , which may contribute to heterogeneous stroma, as suggested by our recent experiments (unpublished data). Therefore, it may be difficult to use only one or two markers to identify these heterogeneous CAFs. The combination of some markers shown above may be a better choice for CAF identification [26] , but the correct combination warrants investigation based on tumor phenotypes.
Activation of CAFs in breast cancer
There is increasing evidence which suggests that CAFs play prominent roles in cancer development and progression; however, the mechanisms for the activation of CAFs are elusive. To date, TGF-β and CXCL12/SDF-1 are regarded as the major tumor cell-derived factors affecting CAF activation [8, 27] through a TGF-β and CXCL12/SDF-1 autocrine signaling loop [8] . Nevertheless, other profibrotic factors released by cancer cells can also act on resident fibroblasts and induce their activation, including PDGF-α/ β [28, 29] , basic fibroblast growth factor (b-FGF) [30] , or interleukin (IL)-6 [31, 32] . Another important mechanism in the activation of CAFs is the downregulation of tumor suppressor genes such as p53, p21, PTEN, and CAV-1, which are also implicated in repressing the procarcinogenic effects of breast stromal fibroblasts both in vitro and in vivo [9] [10] [11] [12] [13] [14] [15] . Interestingly, the findings identified caveolin-1 (Cav-1) as a mediator of CAF activation, and Cav-1 is a well-known marker of oncogenic transformation in fibroblasts [33] . However, the transformation of NIH 3T3 fibroblastic cells by various oncogenes (v-abl, bcr-abl, and crkl) leads to the reduction of caveolins (Cav-1, Cav-2, Cav-3), which correlates very well with the bigger size of colonies formed by these transformed cells [33] . As compared with non-cancer-associated fibroblasts (NAFs), CAFs have a lower level of Cav-1 protein in breast cancer and also grow faster than NAFs, which confirm that loss of Cav-1 means the activation of CAFs [21, 26] . However, the reason for the loss of Cav-1 expression in CAFs still remains a puzzle. Currently, one of the potential possibilities of Cav-1 downregulation in CAFs may be due to lysosomal degradation [26] and autophagy [34] . More recently, another tumor suppressor gene, p16 INK4A , is found downregulated in breast cancer CAFs compared with NAFs isolated from the same patient [35] , which also plays critical roles in the inhibition of cell cycle progression [36] and the induction of senescence [37] . Importantly, p16
INK4A reduction in CAFs induces high levels of CXCL12/SDF-1 and MMP-2, and tumors formed in the presence of p16
INK4A -defective fibroblasts exhibit higher levels of active Akt, Cox-2, MMP-2, and MMP-9. Furthermore, the migration and invasion of breast cancer cells are also enhanced in an SDF-1-dependent manner which is mediated by EMT changes [35] . Moreover, the reduction in p16
INK4A level is due to a decrease in the stability of the CDKN2A mRNA in CAFs, which results from the increase in the expression of the RNA destabilizing protein, AUF1 [35, 38] . Increasingly the p16
INK4A level through ectopic expression or AUF1 downregulation reduces the levels of SDF-1 and MMP-2 and suppresses the pro-carcinogenic effects of CAFs [35] . In this regard, understanding the molecular events by which reactive stromal fibroblasts affect cancer cell is helpful to offer the better therapeutic effect in breast cancer treatment. CAFs promote tumor onset and progression in different ways [39] [40] [41] [42] , such as affecting estradiol (E2) levels; secreting many kinds of factors (HGF,TGF-β,SDF-1,VEGF, IL-6, etc.) and matrix metalloproteinases (MMPs); and inducing stemness, epigenetic changes, EMT, etc. Interestingly, some research have shown that CAFs promote pre-cancerous breast epithelial cells MCF10A and EIII8 growth and inhibit their differentiation by an aromatase-mediated synthesis of estrogen in a three-dimensional cell-cell interaction model [43] . However, another study shows that both NAFs and CAFs have the ability to inhibit the growth of MCF10A [44] . In addition, NAFs have greater inhibitory capacity, and only NAFs significantly inhibit the proliferation of the more transformed MCF10AT cells, suggesting that the ability of fibroblasts to inhibit epithelial cell proliferation is lost during breast cancer development [44] . Furthermore, the conditioned medium from NAFs also inhibits the growth of MCF-7 cells; in contrast, the conditioned medium from CAFs significantly enhances the growth of MCF-7 cells. It dues to increasing 17 beta-estradiol dehydrogenase (E2DH) activity two to threefolds in CAFs, which causes higher level of estradiol (E2) [45] . The result means that CAFs promote the growth of pre-cancerous and cancerous breast epithelial cells by increasing E2 levels, which provides an explanation for the faster tumor growth in estrogen receptor (ER)-positive breast cancer.
Besides affecting the E2 level, increasing growth factors and losing suppressor genes in CAFs also contribute to breast cancer progression. In a mouse xenograft model of breast cancer, transient CAF interactions increase tumor cell malignancy through a TGF-β-mediated mechanism [46] . IL-6 has been found to be 100-fold increased in CAFs compared with NAFs and also promotes migration in MDA-MB-231 cells and induces EMT in ER-positive cell lines (MCF7 or T47D) [32] , suggesting that IL-6 secreted from CAFs potentiates the invasive phenotype in breast cancer. In another mouse model, co-inoculation of CAFs shp21 with MCF7 cells can promote breast cancer development compared with MCF7 cells inoculated alone; the same results are also observed in MDA-MB-231 cell lines [12] . Moreover, when PTEN is overexpressed into CAFs, it can partly inhibit CAF's role on tumor initiation [13] , suggesting that the inactivation of tumor suppressor genes in CAFs also promote breast cancer onset and invasion.
Role of CAFs in invasion and metastasis of breast cancer
CAFs not only induce mammary carcinogenesis but also promote invasion and metastasis in breast cancer [39, 40, 43, 46, 47] . The transition from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) is a good example to understand the process of tumor invasion. It was found that CAFs induced the invasive ability of DCIS epithelial cells both in vitro and in vivo [47, 48] . CAFs achieved this induction of invasion through increasing MMP14 expression and MMP9 activity. Cancer metastasis is a complicated process that requires multiple events including EMT of the epithelial cancer cells, induction of angiogenesis, intravasation and extravasation of cancer cells, EMT cells regaining epithelial traits (mesenchymalto-epithelial transition, MET), and finally forming a new colony in the appropriate distant microenvironment. In this process, not only CAFs but also other stromal cells work together to complete the organ-specific metastasis. It has been shown that CAFs induced EMT changes in breast epithelial cells [32] and also secreted CXCL12/SDF-1 to promote angiogenesis in the primary site by recruiting endothelial progenitor cells [40] . Then, the cancer cells secrete growth factors and chemokines, such as CCL2, not only to activate CAFs but also to recruit the macrophages and promote their intravasation [49] . Furthermore, this study demonstrated that CCL2 secreted from CAFs also increased breast cancer stem cells, which promote metastasis. In another study, it was shown that when breast cancer cells arrived in the lung, CCR-2-positive macrophages promoted their extravasation, and the cancer cells underwent MET and colonized to form lung metastases [50] . In addition, CD4 + FOXP3
+ Treg cells, recruited by CCL5 secreted from CAFs, also promoted lung metastasis by secreting the receptor activator of nuclear factor-kB ligand (RANKL) (Fig. 2) [51] . Interestingly, when breast cancer cells homed to the bone marrow through CXCL12/CXCR4 interaction caused by stem cells and circulating leukocytes [52] , osteoclastic activation was induced by parathyroid hormone-related protein (PTHrP) and other soluble mediators released from the metastatic cells [53] ; at the same time, bone-derived TGF-β also enhanced this process and tumor growth in a TGF-β-RANKL-PTHrP manner [54] . Besides, CCL18 from tumor-associated macrophages (TAMs) also promote metastasis in breast cancer via PITPNM3 [55] . Interestingly, in addition to CAFs, NAFs also promote metastasis in breast cancer. One study found that NAFs promoted the metastasis of prometastatic cancer cells (MCF10CA1a) in vitro and in vivo by TGF-β1 secreted by fibroblasts [46] . The evidence above shows that both in the primary and secondary cancer metastatic site, CAFs and other stromal cells may simultaneously contribute to tumor growth, invasion, metastasis, and metastatic progression (Fig. 2 ).
CAFs and epigenetic modification
Research focused on the origins of cancer have identified that genetic mutations or epigenetic modifications within tumor cells are critical in tumorigenesis and progression. However, there is less genetic evidence supporting a role for genetic changes in breast cancer stroma as contributing to cancer progression [56, 57] . Serial analyses demonstrated that epigenetic changes in breast cancer cells can foster tumor malignancy; however, there are also dramatic and consistent modifications in gene expression within the fibroblasts from primary human breast tumors [58] . These changes include histone modifications and alterations in the expression of DNA methyltransferases, chromatin modifying factors, and microRNAs [57, 59, 60] .
DNA methylation and histone modifications in CAFs
CAFs in breast cancer gain different DNA methylation patterns when compared to NAFs [60] . This has also been found in CAFs isolated from human gastric carcinomas [61] , pancreatic cancers [62] , and pulmonary fibrosis [63] . The CXorf12 gene has been found hypomethylated in breast CAFs [57] , but its role in breast cancer progression still remains unclear. CYP19, encoding cytochrome aromatase p450, is another gene that has been found hypomethylated in breast adipose fibroblasts which induce an increased aromatase levels in the breast [64] . Histone H3K27 also is hypomethylated in breast CAFs, resulting in the high level of ADAM metallopeptidase with thrombospondin type 1 motif (ADAMTS1) in CAFs, which correlates to a more invasive phenotype [65] . Moreover, loss of histone deacetylase 1 expression induces increased osteopontin expression within the stromal compartment of invasive breast cancers, which then activates CAFs to promote tumor growth in vivo. These results suggest that histone modulations are presented in CAFs. All evidence above indicates that DNA methylation and histone modifications in CAFs also induce cancer progression and provide an enhanced understanding of cancer-stromal interactions in cancer evolution.
Role of microRNA in CAFs
MicroRNAs are a class of short non-coding regulatory RNAs that are involved in stem cell maintenance, developmental programming and cell fate specification, as well as various disease pathogeneses [66] [67] [68] [69] . MicroRNA altered gene expression (both in tumor stroma as well as tumor cells) has been implicated in cancer promotion in several MET changes, finally forming secondary tumors. CSF-1 colony stimulating factor 1, EGF epithelial growth factor, CCL2,5 chemokine ligand 2,5, RANKL nuclear factor-κB ligand, VEGF vascular endothelial growth factor types of cancers, including breast cancer [70] [71] [72] [73] [74] [75] . However, the contribution of specific microRNAs to CAFs remains largely unknown. miR21 has been found overexpressed in both tumor cells and breast tumor stroma [71] , which significantly correlates with the dual overexpression of TGF-β and poor patient outcome in breast cancer [76] . miR148-a is downregulated in endometrial CAFs compared to its counterpart NAFs and then promotes migration by WNT10B [77] . One study shows that in endometrial cancer, there are 11 differential expression microRNAs in CAFs and NAFs, and miR-31 is the most downregulated microRNA in CAFs, in which the overexpression of miR-31 significantly impaired the ability of CAFs to stimulate tumor cell migration and invasion without affecting tumor cell proliferation [78] . In 23 prostate cancer cases, the downregulation of miR-15 and miR-16 in CAFs promoted tumor growth and progression through the reduced posttranscriptional repression of Fgf-2 and its receptor Fgfr1, which affect both stromal and tumor cells and enhance cancer cell survival, proliferation, and migration. Moreover, reconstitution of miR-15 and miR-16 impaired the tumor-supportive capability of stromal cells in vitro and in vivo [79] . Currently, while there is not much evidence describing microRNA changes in CAFs in breast cancer, these interesting findings from other tumors may offer some clues that the role of microRNA changes in CAFs and their potential importance in breast cancer progression.
CAFs and therapeutic resistance
Therapeutic resistance is the major reason for breast cancer treatment failure. More importantly, tumor stroma also participates in therapeutic resistance which contributes to breast cancer progression and poor prognosis. Recently, increasing evidence shows that CAFs can induce endocrine/chemotherapy and target therapeutic resistances in breast cancer treatment [5, 80, 81] . Therefore, targeting the stroma as opposed to just targeting tumor cells provides a novel notion and potentially more effective treatment strategy for breast cancer [82] .
CAFs and chemotherapy resistance
Collagen type I secreted by CAFs contributes to decreasing chemotherapeutic drug uptake in tumors and plays a significant role in regulating tumor sensitivity to a variety of chemotherapies [5] . Furthermore, using construct, an oral DNA vaccine targeting FAP can greatly suppress primary tumor cell growth and metastasis of multidrug-resistant murine breast carcinoma [5] . The results suggest that targeting relatively stable fibroblasts maybe an emerging new effective therapy for breast cancer prevention and treatment. In addition, chemotherapy-and radiation-induced DNA damage in fibroblasts promotes the secretion of WNT16B and consequently results in breast cancer cell proliferation and invasion and induces mitoxantrone (MIT) resistance by NF-kB pathway activation. Moreover, the β-catenin inhibitor XAV939 and NF-KB mutation can reverse the sensitivity to MIT [81] , which is also observed in prostate cancer and ovary cancer [81] . The findings suggest that between treatment time periods, cancer cells have a chance to recover through the Wnt signaling pathway; however, adding a Wnt pathway inhibitor may allow for the cancer to restore sensitivity to the original chemotherapy.
CAFs and endocrine resistance
In addition to the induction of chemo-resistance, CAFs can also induce endocrine resistance. Tamoxifen is a classic endocrine therapeutic drug for ER-positive breast cancer patients and greatly improves disease-free survival and overall survival in more than 15 years of follow-up, but about 33 % patients still have recurrence and metastasis [83] . Recently, many results indicate that CAFs play critical roles in tamoxifen resistance. One study showed that when co-cultured with CAFs from ER-α The results also indicated that CAF-induced tamoxifen resistance was accompanied by mitogenactivated protein kinase (MAPK) and Akt hyperactivation, reduced sensitivity to U0126 or LY294002, and ER-α hyperphosphorylation in the activation function-1 domain, but not mediated by epidermal growth factor receptor (EGFR) or insulin-like growth factor-1R (IGF-1R) axes [84] . Another study found that CAF induced tamoxifen and fulvestrant resistance with 4.4-and 2.5-fold reductions in MCF7 by changing mitochondrial functions in cancer cells, and mitochondrial "poisons" (metformin and arsenic trioxide, ATO) are able to re-sensitize these cancer cells to tamoxifen [80] . The findings suggest that CAF-induced mitochondrial dysfunction in breast cancer cells can change their sensitivity to tamoxifen. Notably, the conditioned media of CAFs induce tamoxifen resistance also through the activation of EGFR and PI3K/AKT pathway, with the involvement of β1 integrin [85] . Indeed, our recent results further confirmed that inflammatory cytokines from the conditioned media of CAFs result in tamoxifen resistance through the induction of EMTs (unpublished data). Therefore, tamoxifen resistance modulated by CAFs in breast cancer treatment may provide an alternative explanation for why some patients become refractory to hormone therapy.
CAFs and target resistance
Emerging evidence also indicates that CAFs also induced target resistance in breast cancer and other types of cancers [86] [87] [88] . The results showed that HGF secreted by CAFs activated Met and led to EGFR/Met cross-talk and resistance to EGFR TKIs gefitinib in triple-negative breast cancer (TNBC) [86] , which indicates that targeting EGFR and Met in combination may be an effective therapeutic strategy for TNBC. Interestingly, one study suggested that CAFs can also sensitize some cancers to targeted therapy. Specifically, it was shown that MSCs and CAFs increased the cytotoxic effect of the RAF inhibitor RAF265 on MDA-MB-231 cells by downregulating ERK1/2 phosphorylation and sensitized MCF7 cells to the mTOR inhibitor RAD001 [88] . Moreover, the data indicated that both MSCs and CAFs have no effect on the response to PDGFR/FGFR/VEGFR inhibitor TKI258 in breast cancer cell lines [88] . This observation showed that CAFs may not contribute to all mechanisms of drug resistance; however, the potential reason may be ascribed to the heterogeneity of CAFs in drug response. Based on these findings, many new drugs and new combinations have been emerging to improve breast cancer patients treatment by targeting CAFs in therapeutic resistance, such as XAV939 [81] , metformin [77, 80] , and PD0332991 [89] , as shown in Table 1 .
CAFs and breast cancer prognosis
As described above, breast cancers are divided into five molecular subtypes with different prognosis and treatment. With a deeper understanding of the role of tumor microenvironment, it is interesting to explore whether breast cancer is likely to be classified into subtypes based on its different stromal phenotypes. Recently, one group found that 22K oligonucleotide Agilent microarrays can be used to divide breast cancers into four main groups (ECM1-ECM4) according to 278 ECM-related genes [90] . The ECM1 signature (MARCO, PUNC, and SPARC, whose expression levels were associated with breast cancer survival and risk of recurrence) had a poorer prognosis with high expressions of integrins and metallopeptidases and low expressions of several laminin chains [90] . ECM2 tumors were characterized by a more heterogeneous expression of ECM-related genes. ECM3 tumors showed mainly the upregulation of genes encoding macromolecules involved in the maintenance of connective tissue, in particular collagens, laminins, fibrillins, and the matrix-associated proteins [90] . However, the ECM4 group had a favorable outcome and with overexpression of a set of protease inhibitors belonging to the serpin family. These findings support the hypothesis that clinical outcome is strongly related to stromal characteristics. According to differential gene expression patterns in breast tumor stroma, Finak et al. [91] have developed a 26-gene predictor (stroma-derived prognostic predictor) that predicts disease outcome with greater accuracy than predictors or signatures derived from whole tissue. Tumor stroma samples from the good outcome cluster overexpress a distinct set of immune-related genes, including T cell and NK cell markers, indicative of a TH1-type immune response (GZMA, CD52, CD247, CD8A) [91] . Therefore, individuals with this gene expression pattern may provide benefits from treatments targeting tumor cells via the immune response, such as vaccine therapies in the adjuvant setting. More recently, Sloan et al. [92] found that the high levels of caveolin-1 in the stromal tissue surrounding the tumor, rather than within tumor cells, associated strongly with reduced metastasis and improved survival (p<0.0001). Similar results were also observed by another group [93] , which shows that the loss of stromal Cav-1 in human breast cancers is associated with tumor recurrence, metastasis, and poor clinical outcome. Moreover, Farmer et al. [94] reported that a 50-gene signature predicts poor response to anthracycline-based neoadjuvant chemotherapy (5-fluorouracil, epirubicin, and cyclophosphamide in subjects in the EORTC 10994/BIG 00-01 trial), but unable to predict survival in subjects who did not receive chemotherapy, which suggests that the stromal metagene is predictive rather than prognostic. Interestingly, one study divided tumor stroma into three groups-collagen dominant (C), fibroblast dominant (F), or lymphocyte dominant (L)-and found dominant stroma type as an independent predictor of disease-free survival, especially in patients with high-grade tumors. The L type predicted the longest disease-free interval, followed by the F and C types [95] . The results above support a previous study showing that lymphocytic infiltration is associated with favorable prognosis [96] . Notably, in human breast tumors, infiltrating tumor associated macrophages (TAMs) correlate with poor prognostic features [97, 98] , higher tumor grade [99] , and decreased disease-free survival [100, 101] , which will be discussed below.
Other tumor stromal cells and breast cancer
Cancer is a systemic disease within which it may keep an ecosystem encompassing multiple components of tumor and stromal cells that are a prerequisite for tumor cell invasion and metastasis. As shown in Fig. 3 , in addition to CAFs, there are also other types of stroma which play central roles in breast cancer, such as macrophages, endothelial cells, adipocytes, leukocytes, etc.
Tumor associated macrophages (TAMs) and breast cancer
Macrophages are derived from CD34 + bone marrow progenitors that continually proliferate and shed for their progeny into the bloodstream as pro-monocytes. They then develop into monocytes and extravasate into tissues where they differentiate into a specific type of "resident" tissue macrophages. Macrophages are also prominent in the stoma compartment of virtually all types of malignancy [102] .
TAMs are mostly regarded as the M2 phenotype which secretes growth factors that promote angiogenesis [101] [102] [103] [104] [105] [106] , growth [102] , invasion, migration [107] , metastatic spread [108] , and immunosuppression. In breast cancer, infiltrating TAMs correlate with poor prognostic features [97, 109] , higher tumor grade [99] , high vascular grade, increased necrosis [101] , and decreased disease-free survival [100, 101] and overall survival [101] . Recently, one study found that chemokine (C-C motif) ligand 18 (CCL18) was highly expressed in TAMs and promoted the invasion and metastasis of cancer cells by triggering integrin clustering and enhancing their adherence to the extracellular matrix [55] . Importantly, the results indicated that the functional receptor of CCL18, PITPNM3, is able to promote breast cancer progression through the interaction of CCL18 and PITPNM3. Epigenetic changes also impact TAMs. For example, macrophage infiltration associated with miR92a expression in breast cancer tissue, which links to tumor stage and disease-free survival [110] . Another study found that macrophages activated by IL-4 also regulate the invasiveness of breast cancer cells through exosome-mediated delivery of oncogenic miR-223 via the Mef2c/β-catenin pathway [111] . Due to the fact that macrophages are derived from the same cell lineage as osteoclasts, the major target of bisphosphonates (BPs), which also increase apoptosis and decrease proliferation, migration, and invasion in breast cancer cell lines and mice models. Therefore, targeting TAMs by BPs is a potential choice, and it also has been used to good effect in vitro and in mouse models [106, [112] [113] [114] [115] [116] [117] [118] [119] . Given that BPs have been FDA-approved for breast cancer patients who have bone metastases, they may be the first effective drugs which target tumor stroma and warrant additional research in clinical trials. modulate the microenvironments within which they inside. SDF-1 stroma-derived factor, TNF-α tumor necrosis factor, TGF-β transforming growth factor-β, NF-κB nuclear factor κB, MMP-7,9,11 matrixmetalloproteinase-7, 9, 11, α-SMA alpha smooth muscle actin, FAP fibroblast activation protein, FSP-1 fibroblast-specific protein, PDGFR-α/β platelet-derived growth factor-α/β receptor, FGF fibroblast growth factor, Cav-1 caveolin-1, IL-1, 4, 6, 10, 13 interleukin-1, 4, 6, 10, 13, E2 estradiol, CCL2, 5, 18 chemokine ligands 2, 5, 18, COLVI collagen VI, HGF hepatocyte growth factor 3.2 Other leukocytes and breast cancer Notably, not only macrophages but also other kinds of infiltrating leukocytes promote breast cancer progression. One study showed that more infiltrating leukocytes were found in DCIS with focal myoepithelial cell layer disruptions [120] , which indicated that leukocytes may promote breast cancer invasive progress. In a spontaneous mouse model of breast cancer, CD4 + Treg lymphocytes were found increasingly infiltrated in tumor, and depletion of these T cells by IL-2 immunotoxin fusion protein can inhibit tumor growth [121] . Another study showed that the metastatic spread of ErbB-2-transformed carcinoma cells required CD4 + CD25
+ T cells which secrete RANKL and implicate into the metastatic process [51] . Moreover, the cells which secrete RANKL also have a high expression of forkhead box P3 (FOXP3), a transcription factor produced by regulatory T cells, so the CD4 + CD25
+ FOXP3 + Treg cells can stimulate the metastatic progression by RANKL in the RANK-expressing breast/mammary carcinoma cells. This indicates that anti-RANKL-RANK maybe an effective strategy to prevent breast cancer metastasis. Interestingly, recent findings also suggest that infiltrating number of CD8 + T lymphocytes positively correlate with patient survival [122] and that high CD8 and low FOXP3 cells infiltrating after neoadjuvant chemotherapy were significantly related to improved recurrence-free survival and overall survival (OS). Based on these findings, targeting immune cells may be an emerging strategy for cancer treatment. Indeed, blockade of macrophage recruitment with colony stimulating factor 1 receptor (CSF1R) signaling antagonists is a good example [97] . Cytotoxic agents induced cancer cells to produce CSF1 and interleukin-34 and recruited monocytes/macrophages infiltrating in a CSF1R-dependent manner, and in a mammary tumor-bearing mice model, CSF1R antagonist and paclitaxel in combination improved survival by slowing primary tumor development and reducing pulmonary metastasis in a CD8 + T-cell-dependent manner [97] . Recently, another study showed that different components of leukocytes play different roles in breast cancer [123] . They found that activated T lymphocytes predominate in tumor tissue, whereas myeloid lineage cells predominate in "normal" breast tissue [123] . Importantly, compared with tissues from patients treated primarily by surgery alone, tissues from patients who received neoadjuvant chemotherapy contained increased percentages of infiltrating myeloid cells, accompanied by an increased CD8/CD4 T cell ratio and higher numbers of granzyme B-expressing cells. This study indicates that chemotherapy may affect the tumor immune environment and that a deeper understanding of this interaction should be pursued.
Endothelial cells and breast cancer
Endothelial cells also play important roles in cancer growth and invasion. Human umbilical endothelial cells (HUVECs) induced the higher proliferation of preneoplastic MCF10AT1-EIII8 (referred as EIII8) in EIII8-fibroblasts-HUVEC tricultures than EIII8-fibroblast co-cultures [43] . This finding suggests that endothelial cells can help breast cancer initiation. Moreover, TNF-α production by endothelial and other stromal cells induced by chemotherapeutic agents increases the CXCL1/2 expression in cancer cells via NF-κB and then CXCL1/2 attract CD11b + Gr1 + myeloid cells into the tumor, which produce chemokines including S100A8/9 that enhance cancer cell survival, thus amplifying the CXCL1/2-S100A8/9 loop and causing chemoresistance. This network of endothelial-carcinoma-myeloid signaling interactions provides a mechanism linking chemoresistance and metastasis, with opportunities for intervention by a CXCR2 blocker [124] . This network also highlights that tumor stroma components have interactions in promoting malignancy in cancer cells.
Adipose tissue and breast cancer
Adipose tissue, consisting of mainly mature adipocytes and progenitors (preadipocytes and adipose-derived stem cells, ADSCs), is the most abundant component surrounding breast cancer cells. There is cumulative evidence supporting that cancer-associated adipose (CAA) tissue is a key component of breast cancer progression and carcinogenesis. It has been shown that collagen VI (COLVI) is abundantly expressed in CAAs and involved in mammary tumor progression in vivo [125, 126] . Moreover, IL-6 plays a role in CAA-cancer cell interaction and promotes an aggressive phenotype in prostate cancer [127] . There is also evidence that ADSCs promote the growth and survival of breast cancer cells as well as their migratory and invasive capacities in vitro and in vivo by secreting cytokines (IL-6, IL8, CCL-5, and CXCL12/SDF-1), the expansion of cancer stem cells, and inducing EMT in the cancer cells in a PDGFdependent manner [128] [129] [130] [131] [132] [133] . Like CAFs, CAAs also contribute to radioresistance in breast cancer [134] . The role of CAAs in breast cancer progression may explain that obesity is an independent negative prognosis factor for breast cancer independently of menopause status [135, 136] .
Conclusions
The tumor microenvironment has been demonstrated to promote breast cancer initiation, growth, migration, metastasis, and therapeutic resistance. CAFs, TAMs, EC, CAAs, leukocytes, etc., are critical components of tumor stroma which compromise the tumor microenvironment and take part in the induction of malignancy in breast cancer through various mechanisms (Figs. 2 and 3 ). Research to date provide a greater understanding of cancer evolution, potential targets to reverse refractory tumors into a sensitive phenotype, and improve disease-free survival and overall survival. Moreover, with the novel concept that the best therapy is personalized treatment in breast cancer patients, it is important to explore more biologic markers to categorize patients into a specific and confirmed subtype and use effective markers to predict therapeutic response. The interaction between cancer cells and stromal cells in the tumor microenvironment may be useful to screen potential candidate markers and provide a great impact in cancer therapy in the future.
